Aberdeen Group plc Buys 210,835 Shares of Denali Therapeutics Inc. $DNLI

Aberdeen Group plc grew its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 23.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,113,586 shares of the company’s stock after purchasing an additional 210,835 shares during the period. Aberdeen Group plc owned approximately 0.76% of Denali Therapeutics worth $16,169,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in DNLI. Norges Bank purchased a new stake in Denali Therapeutics during the second quarter valued at $55,224,000. Geode Capital Management LLC lifted its stake in Denali Therapeutics by 4.4% in the second quarter. Geode Capital Management LLC now owns 3,172,305 shares of the company’s stock worth $44,386,000 after purchasing an additional 135,129 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Denali Therapeutics by 58.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,672,078 shares of the company’s stock worth $22,732,000 after acquiring an additional 614,555 shares during the last quarter. Fisher Asset Management LLC boosted its stake in shares of Denali Therapeutics by 11.1% during the second quarter. Fisher Asset Management LLC now owns 1,515,991 shares of the company’s stock valued at $21,209,000 after purchasing an additional 151,032 shares during the period. Finally, Principal Financial Group Inc. boosted its position in Denali Therapeutics by 18.5% in the 3rd quarter. Principal Financial Group Inc. now owns 1,271,190 shares of the company’s stock valued at $18,458,000 after buying an additional 198,207 shares during the period. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Stifel Nicolaus set a $37.00 price objective on shares of Denali Therapeutics in a research note on Monday, November 17th. UBS Group assumed coverage on Denali Therapeutics in a report on Wednesday, January 7th. They set a “buy” rating for the company. Wedbush lowered their target price on shares of Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating for the company in a research note on Thursday, December 11th. BTIG Research reiterated a “buy” rating and set a $32.00 price target on shares of Denali Therapeutics in a research note on Friday, February 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Denali Therapeutics in a research note on Wednesday, January 21st. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Denali Therapeutics has a consensus rating of “Buy” and an average target price of $32.27.

Insider Activity

In related news, insider Alexander O. Schuth sold 17,218 shares of the business’s stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total transaction of $284,097.00. Following the completion of the transaction, the insider owned 282,828 shares in the company, valued at approximately $4,666,662. The trade was a 5.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Ryan J. Watts sold 35,198 shares of the stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total transaction of $580,767.00. Following the completion of the transaction, the chief executive officer directly owned 296,833 shares in the company, valued at $4,897,744.50. This trade represents a 10.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 12.50% of the company’s stock.

Denali Therapeutics Stock Down 0.3%

Shares of DNLI opened at $19.23 on Thursday. The stock has a market capitalization of $2.82 billion, a price-to-earnings ratio of -6.61 and a beta of 1.02. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.79 and a current ratio of 9.79. Denali Therapeutics Inc. has a one year low of $10.57 and a one year high of $23.77. The stock has a 50 day moving average price of $18.54 and a 200 day moving average price of $16.76.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.